The U.S. Food and Drug Administration accepted for Priority Review Pfizer Inc.’s Biologics License Application for TicoVac, the company’s tick-borne encephalitis vaccine for active immunization to prevent TBE in individuals 1 year of age and older.

AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.

A summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.

Verrica Pharmaceuticals Inc. submitted a New Drug Application to the U.S. Food and Drug Administration for VP-102 (cantharidin 0.7% topical solution) for the treatment of molluscum contagiosum.

The U.S. Food and Drug Administration approved Fera’s New Drug Application for Avaclyr (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis.

A global coalition set up to fight emerging epidemics struck a $31 million deal with scientists at Japan’s University of Tokyo to speed up work on a vaccine against a brain-damaging disease caused by the Nipah virus.

GO Therapeutics, with headquarters in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.

Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.